Given the pervasiveness of Non-alcoholic Fatty Liver Disease (NAFLD), updated practice guidelines are worth a look (Hepatology 2012; 55: 2005-23, also in Gastroenterology 2012; 142: 1592-1609)). While the review includes updated information on incidence, prevalence, risk groups, natural history, the focus remains on specific graded recommendations.
These AGA/AASLD/ACG guidelines do not recommend screening adults due to uncertainties surrounding diagnostic tests and treatment. This includes high risk populations such as diabetics and bariatric patients. In addition, unlike recent obesity guidelines from the AAP (Pediatrics 2007; 120: S164-192), these guidelines do not recommend screening children for NAFLD.
Specific management recommendations:
- Exclude competing etiologies in patients with suspected NAFLD: iron studies, autoantibodies, Wilson’s, viral hepatitis, celiac serology, muscle disease
- Consider liver biopsy in higher risk patients: metabolic syndrome patients, patients with higher NAFLD Fibrosis score, or before treatment
- Serum/plasma CK18 is promising biomarker. Not recommended for routine practice at this time.
Treatment Recommendations:
- Weight loss (3-5%) helps steatosis and greater losses (up to 10%) may be needed to improve necroinflammation.
- Metformin –not recommended for liver disease in NASH/NAFLD.
- Pioglitazone can be used to treat steatohepatitis; however, “long-term safety and efficacy of pioglitazone in patients with NASH is not established.”
- Vitamin E at 800 units/day improves liver histology in biopsy-proven NASH. Not recommended without biopsy-confirmed NASH, in diabetic patients, or patients with cirrhosis. Concern with Vitamin E in adults has been an association with increased all-cause mortality in some studies (but not in others).
- Avoid alcohol in patients with NAFLD
Website to download PDF version:
Another opinion on which patients to biopsy:
Related posts:
Pingback: Can NALFD be improved with bile acid sequestration? | gutsandgrowth
Pingback: Six year outcomes with bariatric surgery | gutsandgrowth
Pingback: Does NAFLD cause hepatocellular cancer? | gutsandgrowth
Pingback: Could Cysteamine help NAFLD? | gutsandgrowth
Pingback: Checklists for Crisis and Daily Care | gutsandgrowth
Pingback: Pediatric NAFLD histology score | gutsandgrowth
Pingback: Gut microbiome and endogenous alcohol | gutsandgrowth
Pingback: Most Popular Posts | gutsandgrowth
Pingback: In NASH, is ALT Wrongly Used as a Marker of Liver Injury? | gutsandgrowth
Pingback: Fatty Liver at Birth | gutsandgrowth
Pingback: When Will MRI Obviate the Need for a Liver Biopsy in Pediatric NAFLD? | gutsandgrowth
Pingback: Concise Review: Fatty Liver in Pediatrics | gutsandgrowth
Pingback: Most Popular Posts 2011-2018 | gutsandgrowth